Status:
COMPLETED
Use of an Oral Beta-2 Agonist in Persons With Spinal Cord Injury
Lead Sponsor:
US Department of Veterans Affairs
Conditions:
Spinal Cord Injury
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
PHASE3
Brief Summary
The primary purpose of this study is to determine the effect of administration of the oral beta-2 adrenergic agonist, albuterol, on respiratory muscle strength in individuals with cervical (neck) and ...
Eligibility Criteria
Inclusion
- Chronic Spinal Cord Injury (\>1 year post-injury)
- All American Spinal Injury Association (ASIA) classifications
- High Paraplegia (level of injury T1-T6)
- Tetraplegia (level of injury C2-C8, non-ventilator dependent)
Exclusion
- history of asthma
- uncontrolled hypertension or cardiovascular disease
- those using beta-2 adrenergic agonists
- epilepsy or seizure disorder
- hyperthyroidism
- chronic corticosteroid use
- those taking monoamine oxidase inhibitors or Tricyclic antidepressants for depression
- hypersensitivity to albuterol or any of its' delete components
- pregnancy
- use of ergogenic aids or supplements with anabolic characteristics including, but not limited to:
- creatine monohydrate
- anabolic steroids (e.g., testosterone)
- growth hormone and their analogs and/or derivatives
Key Trial Info
Start Date :
April 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2014
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00755079
Start Date
April 1 2007
End Date
December 1 2014
Last Update
March 17 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
VA Medical Center, Bronx
The Bronx, New York, United States, 10468